A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2018
At a glance
- Drugs DSP-0337 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Boston Biomedical
- 17 Sep 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 30 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Apr 2018.